aTENSION.life

📍 Vienna, Austria🗓 Founded 2024👥 8 employees💰 Last funded Mar 2025

At aTENSION.life, we develop and market innovative and precise diagnostic solutions that enable early and accurate diagnosis as well as targeted - and even personalized - treatment for people with hypertension. Our proprietary ALDO+ technology platform is based on state-of-the-art mass spectrometry and analyzes the Renin-Angiotensin-Aldosterone System (RAAS) with unparalleled precision from a single blood sample. This allows physicians to accurately identify the causes of treatment-resistant hypertension, without the need for trial-and-error approaches. The first product from this platform, ALDO+PA, is a CE-IVD-certified blood test for the diagnosis of Primary Aldosteronism (PA), one of the most common yet often overlooked causes of treatment-resistant hypertension. ALDO+PA delivers reliable results without requiring patients to stop their current medication and is available in Austria through our partnership with labors.at. With our scalable Prep’n’Ship™ model, we make mass spectrometry-based precision diagnostics accessible to any laboratory - regardless of existing infrastructure. We collaborate with physicians, laboratories, and healthcare institutions to set new standards in hypertension diagnostics and sustainably improve cardiovascular care.

Total investors

Early stage

Mid stage

Late stage

2024

Founded